Abstracts tagged "autoantibodies and systemic lupus erythematosus (SLE)"

Abstract Number: 672 • 2012 ACR/ARHP Annual Meeting
Immune Complexes and Autoantibodies to Oxidized Lipids in Systemic Lupus Erythematosus
Yujin Ye¹, Tianfu Wu¹ and Chandra Mohan², ¹Division of Rheumatology/Internal Medicine, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, ²University of Houston, Houston, TX
Background/Purpose: SLE is a chronic autoimmune inflammatory disease. Increasing evidence suggest that excess production of reactive oxygen species (ROS) may cause oxidative stress and favor…
Abstract Number: 677 • 2012 ACR/ARHP Annual Meeting
Antibodies to Oxidized Low Density Lipoprotein or Anti-Lipoprotein Lipase May Lead to More Atherosclerotic Plaque in a Sub-Set of SLE Patients
Biji T. Kurien¹, James Fesmire², Skyler P. Dillon³, Marianne Reichlin⁴, Morris Reichlin⁵ and Robert H. Scofield⁶, ¹College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, ³Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Oklahoma Medical Res Fndn, Oklahoma City, OK, ⁵Arthritis & Imm Laboratory, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁶Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Premature atherosclerosis is associated with systemic lupus erythematosus (SLE). Oxidized low density lipoproteins (oxLDL) are important in atherosclerosis and have been reported in SLE…
Abstract Number: 659 • 2012 ACR/ARHP Annual Meeting
The Small Molecule Activator to ACE2 Prevents the Inhibition of ACE2 Activity by Autoantibodies
Shiori Haga¹, Yuko Takahashi², Yukihito Ishizaka¹ and Akio Mimori², ¹Department of Intractable Diseases, National Center for Global Health and Medicine, Research Institute, Tokyo, Japan, ²Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan
Background/Purpose: Angiotensin-converting enzyme 2 (ACE2) is a member of renin-angiotensin system that plays a critical role in regulating blood pressure and cardiovascular function. It is…
Abstract Number: 670 • 2012 ACR/ARHP Annual Meeting
Prolidase Deficiency Induces Antibodies to Sm, Ro60 and Double Stranded DNA
Biji T. Kurien¹, Anil D'souza², Skyler P. Dillon¹, Benjamin F. Bruner³, Timothy Gross⁴, Judith A. James⁵, Ira N. Targoff⁶, Jacen S. Maier-Moore⁷, Isaac T.W. Harley⁸, Heng Wang⁹ and Robert H. Scofield⁷, ¹Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ²Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Harding University, Searcy, AR, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁷Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁸Cincinnati Children's Hospital Research Foundation, Cincinnati, OH, ⁹Das Deutsch Center Clinic for Special Needs Children, Middlefield, OH
Background/Purpose: Prolidase is a ubiquitous enzyme found in the cytoplasm. The enzyme specifically cleaves dipeptides containing C-terminal proline or hydroxyproline, in one of the last…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].